Advanced search
Publication Cover
HIV Therapy Volume 4, 2010 - Issue 5
Journal homepage
1,586
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent Developments in HIV-Related Kidney Disease

Michelle M Estrella1 Johns Hopkins University School of Medicine, Division of Nephrology, 1830 E. Monument Street, Suite416, Baltimore, MD21205, USA;2 [email protected]
,
Derek M Fine1 Johns Hopkins University School of Medicine, Division of Nephrology, 1830 E. Monument Street, Suite416, Baltimore, MD21205, USA
&
Mohamed G Atta1 Johns Hopkins University School of Medicine, Division of Nephrology, 1830 E. Monument Street, Suite416, Baltimore, MD21205, USA
Pages 589-603 | Published online: 25 Oct 2010

Bibliography

  • Franceschini N , NapravnikS, EronJJ Jr, Szczech LA, Finn WF: Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int.67(4), 1526–1531(2005).
  • Choi AI , LiY, ParikhC, VolberdingPA, ShlipakMG: Long-term clinical consequences of acute kidney injury in the HIV-infected.Kidney Int.78(5), 478–485(2010).
  • Wyatt CM , AronsRR, KlotmanPE, KlotmanME: Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.AIDS20(4), 561–565(2006).
  • Parkhie SM , FineDM, LucasGM, AttaMG: Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis.Clin. J. Am. Soc. Nephrol.5(5), 798–804(2010).
  • Szczech LA , GrunfeldC, ScherzerRet al.: Microalbuminuria in HIV infection.AIDS21(8), 1003–1009(2007).
  • Fernando SK , FinkelsteinFO, MooreBA, WeissmanS: Prevalence of chronic kidney disease in an urban HIV infected population.Am. J. Med. Sci.335(2), 89–94(2008).
  • Jones CY , JonesCA, WilsonIBet al.: Cystatin C and creatinine in an HIV cohort: the Nutrition for Healthy Living Study.Am. J. Kidney Dis.51(6), 914–924(2008).
  • Szczech LA , GuptaSK, HabashRet al.: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.Kidney Int.66(3), 1145–1152(2004).
  • Yadav A , VallabuS, KumarDet al.: HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation.Am. J. Physiol. Renal Physiol.298(3), F734–F744 (2010).
  • Kumar D , KonkimallaS, YadavAet al.: HIV-associated nephropathy: role of mammalian target of rapamycin pathway.Am. J. Pathol.177(2), 813–821(2010).
  • Kimmel PL , PhillipsTM, Ferreira-CentenoA, Farkas-SzallasiT, AbrahamAA, GarrettCT: HIV-associated immune-mediated renal disease.Kidney Int.44(6), 1327–1340(1993).
  • Estrella M , FineDM, GallantJEet al.: HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.Clin. Infect. Dis.43(3), 377–380(2006).
  • Szczech LA , HooverDR, FeldmanJGet al.: Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.Clin. Infect. Dis.39(8), 1199–1206(2004).
  • Estrella MM , ParekhRS, AbrahamAet al.: The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.J. Acquir. Immune Defic. Syndr. (2010) (In press).
  • Choi AI , LiY, DeeksSG, GrunfeldC, VolberdingPA, ShlipakMG: Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons.Circulation121(5), 651–658(2010).
  • George E , LucasGM, NadkarniGN, FineDM, MooreR, AttaMG: Kidney function and the risk of cardiovascular events in HIV-1-infected patients.AIDS24(3), 387–394(2010).
  • Hsu CY , OrdonezJD, ChertowGM, FanD, McCullochCE, GoAS: The risk of acute renal failure in patients with chronic kidney disease.Kidney Int.74(1), 101–107(2008).
  • Lucas GM , LauB, AttaMG, FineDM, KerulyJ, MooreRD: Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races.J. Infect. Dis.197(11), 1548–1557(2008).
  • Freedman BI , SoucieJM, StoneSM, PegramS: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy.Am. J. Kidney Dis.34(2), 254–258(1999).
  • Bruggeman LA , DikmanS, MengC, QuagginSE, CoffmanTM, KlotmanPE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.J. Clin. Invest.100(1), 84–92(1997).
  • Gharavi AG , AhmadT, WongRDet al.: Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3.Proc. Natl Acad. Sci. USA101(8), 2488–2493(2004).
  • Chan KT , PapetaN, MartinoJet al.: Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus.Kidney Int.75(4), 366–372(2009).
  • Papeta N , ChanKT, PrakashSet al.: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression.J. Clin. Invest.119(5), 1178–1188(2009).
  • Quaggin SE : Genetic susceptibility to HIV-associated nephropathy.J. Clin. Invest.119(5), 1085–1089(2009).
  • Imperatore G , HansonRL, PettittDJ, KobesS, BennettPH, KnowlerWC: Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group.Diabetes47(5), 821–830(1998).
  • DeWan AT , ArnettDK, AtwoodLDet al.: A genome scan for renal function among hypertensives: the HyperGEN study.Am. J. Hum. Genet.68(1), 136–144(2001).
  • Kopp JB , SmithMW, NelsonGWet al.: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.Nat. Genet.40(10), 1175–1184(2008).
  • Kao WH , KlagMJ, MeoniLAet al.: MYH9 is associated with nondiabetic end-stage renal disease in African Americans.Nat. Genet.40(10), 1185–1192(2008).
  • Arrondel C , VodovarN, KnebelmannBet al.: Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.J. Am. Soc. Nephrol.13(1), 65–74(2002).
  • Freedman BI , HicksPJ, BostromMAet al.: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.Kidney Int.75(7), 736–745(2009).
  • Freedman BI , KoppJB, WinklerCAet al.: Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study.Am. J. Nephrol.29(6), 626–632(2009).
  • Freedman BI , HicksPJ, BostromMAet al.: Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD.Nephrol. Dial. Transplant.24(11), 3366–3371(2009).
  • Behar DM , RossetS, TzurSet al.: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans.Hum. Mol. Genet.19(9), 1816–1827(2010).
  • Genovese G , FriedmanDJ, RossMDet al.: Association of trypanolytic ApoL1 variants with kidney disease in African Americans.Science329(5993), 841–845(2010).
  • Tzur S , RossetS, ShemerRet al.: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.Hum. Genet.128(3), 345–350(2010).
  • Freedman BI , KoppJB, LangefeldCDet al.: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. (2010) (In press).
  • Winston JA , KlotmanME, KlotmanPE: HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection.Kidney Int.55(3), 1036–1040(1999).
  • Levin ML , PalellaF, ShahS, LermaE, ButterJ, KanwarYS: HIV-associated nephropathy occurring before HIV antibody seroconversion.Am. J. Kidney Dis.37(5), E39 (2001).
  • Bruggeman LA , RossMD, TanjiNet al.: Renal epithelium is a previously unrecognized site of HIV-1 infection.J. Am. Soc. Nephrol.11(11), 2079–2087(2000).
  • Eitner F , CuiY, HudkinsKLet al.: Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease.J. Am. Soc. Nephrol.11(5), 856–867(2000).
  • Zhong J , ZuoY, MaJet al.: Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy.Kidney Int.68(3), 1048–1060(2005).
  • Zuo Y , MatsusakaT, ZhongJet al.: HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis.J. Am. Soc. Nephrol.17(10), 2832–2843(2006).
  • Vallet-Pichard A , PolS: Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.J. Hepatol.44(1 Suppl.), S28–S34 (2006).
  • Wyatt CM , MalvestuttoC, CocaSG, KlotmanPE, ParikhCR: The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis.AIDS22(14), 1799–1807(2008).
  • Mocroft A , KirkO, ReissPet al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.AIDS24(11), 1667–1678(2010).
  • Yanik EL , LucasGM, VlahovD, KirkGD, MehtaSH: HIV and proteinuria in an injection drug user population.Clin. J. Am. Soc. Nephrol. (2010) (In press).
  • Fine DM , GargN, HaasMet al.: Cocaine use and hypertensive renal changes in HIV-infected individuals.Clin. J. Am. Soc. Nephrol.2(6), 1125–1130(2007).
  • Stengel B , CouchoudC: Chronic kidney disease prevalence and treated end-stage renal disease incidence: a complex relationship.J. Am. Soc. Nephrol.17(8), 2094–2096(2006).
  • Muntner P , CoreshJ, SmithJC, EckfeldtJ, KlagMJ: Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.Kidney Int.58(1), 293–301(2000).
  • Brown TT , ColeSR, LiXet al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.Arch. Intern. Med.165(10), 1179–1184(2005).
  • Seaberg EC , MunozA, LuMet al.: Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.AIDS19(9), 953–960(2005).
  • Onen NF , OvertonET, SeyfriedWet al.: Aging and HIV infection: a comparison between older HIV-infected persons and the general population.HIV Clin. Trials11(2), 100–109(2010).
  • Riddler SA , SmitE, ColeSRet al.: Impact of HIV infection and HAART on serum lipids in men.JAMA289(22), 2978–2982(2003).
  • Choi AI , ShlipakMG, HuntPW, MartinJN, DeeksSG: HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy.AIDS23(16), 2143–2149(2009).
  • Nguyen MT , MaynardSE, KimmelPL: Misapplications of commonly used kidney equations: renal physiology in practice.Clin. J. Am. Soc. Nephrol.4(3), 528–534(2009).
  • Mehta RL , KellumJA, ShahSVet al.: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury.Crit. Care11(2), R31 (2007).
  • Gupta SK , EustaceJA, WinstonJAet al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.Clin. Infect. Dis.40(11), 1559–1585(2005).
  • Siedner MJ , AttaMG, LucasGM, PerazellaMA, FineDM: Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients.J. Acquir. Immune Defic. Syndr.47(2), 261–263(2008).
  • Levey AS , CoreshJ, BalkEet al.: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Ann. Intern. Med.139(2), 137–147(2003).
  • Ginsberg JM , ChangBS, MatareseRA, GarellaS: Use of single voided urine samples to estimate quantitative proteinuria.N. Engl. J. Med.309(25), 1543–1546(1983).
  • Price CP , NewallRG, BoydJC: Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review.Clin. Chem.51(9), 1577–1586(2005).
  • Cockcroft DW , GaultMH: Prediction of creatinine clearance from serum creatinine.Nephron16(1), 31–41(1976).
  • Levey AS , BoschJP, LewisJBet al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.Ann. Intern. Med.130, 461–470(1999).
  • Levey AS , GreeneT, KusekJWet al.: A simplified equation to predict glomerular filtration rate from serum creatinine.J. Am. Soc. Nephrol.11, 115A (2000).
  • Levey AS , CoreshJ, GreeneTet al.: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.Ann. Intern. Med.145(4), 247–254(2006).
  • Levey AS , StevensLA, SchmidCHet al.: A new equation to estimate glomerular filtration rate.Ann. Intern. Med.150(9), 604–612(2009).
  • Rule AD , LarsonTS, BergstralhEJ, SlezakJM, JacobsenSJ, CosioFG: Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.Ann. Intern. Med.141(12), 929–937(2004).
  • Bostom AG , KronenbergF, RitzE: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels.J. Am. Soc. Nephrol.13(8), 2140–2144(2002).
  • Huang E , HewittRG, SheltonM, MorseGD: Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease.Pharmacotherapy16(2), 222–229(1996).
  • Noormohamed SE , KatseresJK, StapletonJT: Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals.Ren. Fail.20(4), 627–633(1998).
  • Smith BL , SarnoskiTP, DennisS, LukeDR: Failure of predicted creatinine clearance equations in HIV-seropositive patients.Int. J. Clin. Pharmacol. Ther. Toxicol.30(10), 394–399(1992).
  • Barraclough K , ErL, NgF, HarrisM, MontanerJ, LevinA: A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population.Nephron Clin. Pract.111(1), c39–c48 (2009).
  • Shlipak MG , Wassel FyrCL, ChertowGMet al.: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol.17(1), 254–261(2006).
  • Kottgen A , SelvinE, StevensLA, LeveyAS, Van LenteF, CoreshJ: Serum cystatin C in the united states: The Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis.51(3), 385–394(2008).
  • Stevens LA , CoreshJ, SchmidCHet al.: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.Am. J. Kidney Dis.51(3), 395–406(2008).
  • Stevens LA , SchmidCH, GreeneTet al.: Factors other than glomerular filtration rate affect serum cystatin C levels.Kidney Int.75(6), 652–660(2009).
  • Odden MC , ScherzerR, BacchettiPet al.: Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.Arch. Intern. Med.167(20), 2213–2219(2007).
  • Mauss S , BergerF, KuschakDet al.: Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients.Antivir. Ther.13(8), 1091–1095(2008).
  • Mocroft A , WyattC, SzczechLet al.: Interruption of antiretroviral therapy is associated with increased plasma cystatin C.AIDS23(1), 71–82(2009).
  • Bernard AM , MoreauD, LauwerysR: Comparison of retinol-binding protein and b2-microglobulin determination in urine for the early detection of tubular proteinuria.Clin. Chim. Acta126(1), 1–7(1982).
  • Norden AG , ScheinmanSJ, Deschodt-LanckmanMMet al.: Tubular proteinuria defined by a study of dent‘s (CLCN5 mutation) and other tubular diseases.Kidney Int.57(1), 240–249(2000).
  • Price RG : The role of NAG (N-acetyl-β-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity.Clin. Nephrol.38(Suppl. 1), S14–S19 (1992).
  • Kuwabara T , MoriK, MukoyamaMet al.: Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons.Kidney Int.75(3), 285–294(2009).
  • Hall AM , EdwardsSG, LapsleyMet al.: Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.Am. J. Kidney Dis.54(6), 1034–1042(2009).
  • Landro L , DamasJK, FloTHet al.: Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: Increase during highly active anti-retroviral therapy.Clin. Exp. Immunol.152(1), 57–63(2008).
  • Soler-Garcia AA , JohnsonD, HathoutY, RayPE: Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases.Clin. J. Am. Soc. Nephrol.4(4), 763–771(2009).
  • Paragas N , NickolasTL, WyattCet al.: Urinary NGAL marks cystic disease in HIV-associated nephropathy.J. Am. Soc. Nephrol.20(8), 1687–1692(2009).
  • Tabatabai S , SperatiCJ, AttaMGet al.: Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection.Clin. J. Am. Soc. Nephrol.4(11), 1766–1773(2009).
  • Choi AI , RodriguezRA, BacchettiPet al.: Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.Clin. Infect. Dis.45(12), 1633–1639(2007).
  • Lucas GM , EustaceJA, SozioS, MentariEK, AppiahKA, MooreRD: Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.AIDS18(3), 541–546(2004).
  • Yahaya I , UthmanAO, UthmanMM: Interventions for HIV-associated nephropathy.Cochrane Database Syst. Rev.4, CD007183 (2009).
  • Hammer SM , EronJJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA300(5), 555–570(2008).
  • Eustace JA , NuermbergerE, ChoiM, ScheelPJ Jr, Moore R, Briggs WA: Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int.58(3), 1253–1260(2000).
  • Cihlar T , HoES, LinDC, MulatoAS: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs.Nucleosides Nucleotides Nucleic Acids20(4–7), 641–648(2001).
  • Ray AS , CihlarT, RobinsonKLet al.: Mechanism of active renal tubular efflux of tenofovir.Antimicrob. Agents Chemother.50(10), 3297–3304(2006).
  • Kohler JJ , HosseiniSH, Hoying-BrandtAet al.: Tenofovir renal toxicity targets mitochondria of renal proximal tubules.Lab. Invest.89(5), 513–519(2009).
  • Peyriere H , ReynesJ, RouanetIet al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.J. Acquir. Immune Defic. Syndr.35(3), 269–273(2004).
  • Mathew G , KnausSJ: Acquired Fanconi‘s syndrome associated with tenofovir therapy.J. Gen. Intern. Med.21(11), C3–C5 (2006).
  • Earle KE , SeneviratneT, ShakerJ, ShobackD: Fanconi‘s syndrome in HIV+ adults: report of three cases and literature review.J. Bone Miner. Res.19(5), 714–721(2004).
  • Di Biagio A , RossoR, MonteforteP, RussoR, RovettaG, ViscoliC: Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.J. Med. Case Reports3, 8136 (2009).
  • Perrot S , AslangulE, SzwebelT, Caillat-VigneronN, Le Jeunne C: Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J. Clin. Rheumatol.15(2), 72–74(2009).
  • Rollot F , NazalEM, Chauvelot-MoachonLet al.: Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir–ritonavir–didanosine.Clin. Infect. Dis.37(12), e174–e176 (2003).
  • Coca S , PerazellaMA: Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.Am. J. Med. Sci.324(6), 342–344(2002).
  • Gallant JE , StaszewskiS, PozniakALet al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA292(2), 191–201(2004).
  • Izzedine H , HulotJS, VittecoqDet al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. data from a double-blind randomized active-controlled multicentre study.Nephrol. Dial. Transplant.20(4), 743–746(2005).
  • Arribas JR , PozniakAL, GallantJEet al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.J. Acquir. Immune Defic. Syndr.47(1), 74–78(2008).
  • Jones R , StebbingJ, NelsonMet al.: Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case–control study.J. Acquir. Immune Defic. Syndr.37(4), 1489–1495(2004).
  • Gallant JE , ParishMA, KerulyJC, MooreRD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.Clin. Infect. Dis.40(8), 1194–1198(2005).
  • Gallant JE , MooreRD: Renal function with use of a tenofovir-containing initial antiretroviral regimen.AIDS23(15), 1971–1975(2009).
  • Rodriguez-Novoa S , LabargaP, SorianoVet al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.Clin. Infect. Dis.48(11), e108–e116 (2009).
  • Young B , BuchaczK, MoormanA, WoodKC, Brooks JT; HIV Outpatient Study (HOPS) Investigators: Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS23(8), 589–592(2009).
  • Marroni M , GaburriM, MecozziF, BaldelliF: Acute interstitial nephritis secondary to the administration of indinavir.Ann. Pharmacother.32(7–8), 843–844(1998).
  • Brodie SB , KellerMJ, EwensteinBM, SaxPE: Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients.AIDS12(18), 2433–2437(1998).
  • Chan-Tack KM , TruffaMM, StrubleKA, BirnkrantDB: Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration‘s adverse event reporting system.AIDS21(9), 1215–1218(2007).
  • Izzedine H , M‘radMB, BardierA, DaudonM, SalmonD: Atazanavir crystal nephropathy.AIDS21(17), 2357–2358(2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.